Verhoeven E L, Tielliu I F, Bos W T, Zeebregts C J
Department of Surgery, Division of Vascular Surgery, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
Eur J Vasc Endovasc Surg. 2009 Aug;38(2):155-61. doi: 10.1016/j.ejvs.2009.05.002. Epub 2009 Jun 11.
Recent developments with fenestrated and branched stent grafts have opened the way to treat complex aortic aneurysms involving the visceral arteries. Early reports on endovascular treatment of thoraco-abdominal aneurysms have demonstrated the feasibility of the technique. Given the sparse literature, its safety has not been established yet.
A literature review was conducted, and the results of our own series of 30 patients treated with a custom-made Zenith device with fixed branches are presented. Most of the patients were refused open surgery mainly for the extent of the disease combined with co-morbidity, which included in most patients a combination of several risk factors. The mean aneurysm size was 70 mm and the extent of the aneurysm was type I in eight cases, type II in five, type III in 12 and type IV in five patients.
Technical success in our series was achieved in 93% (28/30). Two out of 97 (2%) targeted vessels were lost. In one patient, a renal artery ruptured during insertion of the bridging stent graft. In a second patient, a coeliac artery could not be catheterised and was lost. The 30-day mortality was 6.7% and corroborated with 5.5% in the largest series reported so far. The 6 months and 1-year survival were 89.3% and 76.0%, respectively.
The results of fully endovascular repair of selected thoraco-abdominal aneurysms are promising. A learning curve should be expected. Anatomical limitations such as extremely tortuous vessels and access problems should be taken into account, as well as the quality of the targeted side branches. Although longer-term results need to be awaited, it is likely that endovascular repair of thoraco-abdominal aneurysms will become a preferential treatment option for many patients in the future.
带开窗和分支的支架型人工血管的最新进展为治疗累及内脏动脉的复杂主动脉瘤开辟了道路。关于胸腹主动脉瘤血管内治疗的早期报告已证明了该技术的可行性。鉴于相关文献较少,其安全性尚未确立。
进行了文献综述,并展示了我们自己使用定制的带固定分支的Zenith装置治疗的30例患者的系列结果。大多数患者因疾病范围合并共病而被拒绝接受开放手术,大多数患者存在多种危险因素。动脉瘤平均大小为70mm,动脉瘤范围为Ⅰ型8例,Ⅱ型5例,Ⅲ型12例,Ⅳ型5例。
我们的系列中技术成功率为93%(28/30)。97条目标血管中有2条(2%)丢失。1例患者在插入桥接支架型人工血管时肾动脉破裂。另1例患者,腹腔动脉无法插管而丢失。30天死亡率为6.7%,与目前报道的最大系列中的5.5%相符。6个月和1年生存率分别为89.3%和76.0%。
选择性胸腹主动脉瘤完全血管内修复的结果很有前景。应预期存在学习曲线。应考虑解剖学限制,如血管极度迂曲和入路问题,以及目标侧支的质量。尽管需要等待长期结果,但胸腹主动脉瘤的血管内修复未来可能会成为许多患者的首选治疗方案。